You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

 

Online download statistics by month:

Online download statistics by month: February 2022 to March 2026

AbstractFullPdf
Feb 202210741103563
Mar 2022965992571
Apr 2022592617315
May 2022492507217
Jun 2022410421192
Jul 2022491496165
Aug 2022543561232
Sep 2022530532251
Oct 2022559573213
Nov 2022527529228
Dec 2022396398133
Jan 2023478481199
Feb 2023461461177
Mar 2023516519239
Apr 2023424426159
May 2023404410174
Jun 2023395399150
Jul 2023431435180
Aug 2023394395148
Sep 2023310311127
Oct 2023334336154
Nov 2023305305149
Dec 2023298299154
Jan 2024252252179
Feb 2024439439194
Mar 2024476479268
Apr 2024342342219
May 2024343347192
Jun 2024275275168
Jul 2024290292148
Aug 2024241237125
Sep 2024195198583
Oct 2024376378299
Nov 2024338342294
Dec 2024290298189
Jan 2025301301180
Feb 2025408409243
Mar 2025339343241
Apr 2025338338213
May 2025328329221
Jun 2025210214115
Jul 2025110
Oct 2025111
Jan 2026220
Mar 2026220
Total17116173259162